Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Click editor (CE2) is a second-generation genome editing technology designed for precise genome writing. It consists of an RNA-programmable nickase (such as a CRISPR-Cas enzyme), a DNA-dependent DNA polymerase (DDP), and an HUH endonuclease (HUHe) domain. The HUHe domain facilitates the covalent attachment and recruitment of a single-stranded nucleic acid template (click DNA or clkDNA) that encodes the desired genetic modification. CE2 represents an optimization over the first-generation click editor (CE1) through protein engineering of the HUHe domain and chemical/structural optimization of the clkDNA substrate, resulting in significantly higher editing efficiency and potency at lower doses. The technology is being developed by researchers at Massachusetts General Hospital and the Technical University of Munich for potential therapeutic applications in genetic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on click editor (CE2).